Hormone-dependent breast cancers respond to inhibitors of estrogen synthesis or action with tumor regression and with a reduction of new metastases. The mechanisms underlying the effects of estrogen on metastasis likely differ from those on tumor regression. Cell migration is a key first step in the metastatic process. Based on our prior work and other published data, we designed and tested a working model that suggested that estrogen receptor ␣, epidermal growth factor receptor, focal adhesion kinase (FAK), paxillin, phosphatidylinositol 3 kinase, p60 Src tyrosine kinase (c-Src), c-Jun N-terminal kinase, and MAPK interact to facilitate estradiol (E 2 )-induced cell migration. Accordingly, we examined the effect of E 2 on activation of these pathways and demonstrated mechanistic effects by blocking each component and assessing cell migration as a biologic endpoint. Initial studies validated a robust cell migration assay characterized by highly reproducible, dose-dependent responses to E 2 . Examining various mechanisms involved in migration, we showed that E 2 induced activation of c-Src, FAK, and paxillin with early peaks within 5-30 min and later peaks at 24 h. ERK and protein kinase B phosphorylation exhibited only early peaks. Blockade of various steps in these signaling pathways with use of small interfering RNA or specific inhibitors demonstrated mechanistic effects of these signaling molecules on cell migration. Our results suggest that the effects of E 2 on cell migration involve multiple, interacting signaling pathways. E strogens stimulate the growth of hormone-dependent breast cancers by increasing cellular proliferation and inhibiting apoptosis. By abrogating these effects, administration of aromatase inhibitors or antiestrogens delays tumor recurrence in the adjuvant treatment setting and causes regression of advanced breast cancer (1). These therapeutic strategies also reduce the frequency of distant metastases, presumably through interruption of additional pathways (1). The metastatic process is complex and requires several steps, including cellular invasion through blood vessels, travel through the circulation to distant organs, reentry into tissue, and growth at the new sites (2-5). The ability of cells to migrate in tissue is essential to the metastatic process and represents its initial step (3). In our earlier studies, we observed effects of estradiol (E 2 ) on the morphology of hormone-dependent breast cancer cells with formation of filopodia, lamellipodia, and pseudopodia within 20 min of administration (6). Such dynamic cell membrane changes are hallmarks of cells that are preparing for migration (7). These observations initially led us to question whether estrogen exerts effects on cell Abbreviations: Akt, Protein kinase B; CRKII, V-crk sarcoma virus CT10 oncogene homolog; c-Src, p60 Src tyrosine kinase; DCC, dextran-coated charcoal; DOCK180, dedicator of cytokinesis; E 2 , estradiol; EGF-R, epidermal growth factor receptor; ELMO, engulfment and cell motility; ER, estrogen receptor; FAK, focal adhesion kinase; FBS, fetal bovine serum; JNK, c-Jun N-terminal kinase; PAK, p21-activated kinase; PI, phosphatidylinositol; PP2, 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo [3,4-d]pyrimidine; Rac, Rho family GTPase; ROCK, Rhoassociated protein kinase; siRNA, small interfering RNA; VAV2, guanine nucleotide exchange factor vav2; Y118, tyrosine 118 residual.
Hormone-dependent breast cancers respond to inhibitors of estrogen synthesis or action with tumor regression and with a reduction of new metastases. The mechanisms underlying the effects of estrogen on metastasis likely differ from those on tumor regression. Cell migration is a key first step in the metastatic process. Based on our prior work and other published data, we designed and tested a working model that suggested that estrogen receptor ␣, epidermal growth factor receptor, focal adhesion kinase (FAK), paxillin, phosphatidylinositol 3 kinase, p60 Src tyrosine kinase (c-Src), c-Jun N-terminal kinase, and MAPK interact to facilitate estradiol (E 2 )-induced cell migration. Accordingly, we examined the effect of E 2 on activation of these pathways and demonstrated mechanistic effects by blocking each component and assessing cell migration as a biologic endpoint. Initial studies validated a robust cell migration assay characterized by highly reproducible, dose-dependent responses to E 2 . Examining various mechanisms involved in migration, we showed that E 2 induced activation of c-Src, FAK, and paxillin with early peaks within 5-30 min and later peaks at 24 h. ERK and protein kinase B phosphorylation exhibited only early peaks. Blockade of various steps in these signaling pathways with use of small interfering RNA or specific inhibitors demonstrated mechanistic effects of these signaling molecules on cell migration. Our results suggest that the effects of E 2 on cell migration involve multiple, interacting signaling pathways. Important effects are mediated by the MAPK, phosphatidylinositol 3 kinase, and c-Jun N-terminal kinase pathways and use FAK, paxillin, and c-Src for activation. Each pathway represents a potential target for blocking cell migration and metastasis of breast cancer cells. (Endocrinology 151: 5146 -5156, 2010) E strogens stimulate the growth of hormone-dependent breast cancers by increasing cellular proliferation and inhibiting apoptosis. By abrogating these effects, administration of aromatase inhibitors or antiestrogens delays tumor recurrence in the adjuvant treatment setting and causes regression of advanced breast cancer (1) . These therapeutic strategies also reduce the frequency of distant metastases, presumably through interruption of additional pathways (1) . The metastatic process is complex and requires several steps, including cellular invasion through blood vessels, travel through the circulation to distant organs, reentry into tissue, and growth at the new sites (2) (3) (4) (5) . The ability of cells to migrate in tissue is essential to the metastatic process and represents its initial step (3) . In our earlier studies, we observed effects of estradiol (E 2 ) on the morphology of hormone-dependent breast cancer cells with formation of filopodia, lamellipodia, and pseudopodia within 20 min of administration (6) . Such dynamic cell membrane changes are hallmarks of cells that are preparing for migration (7) . These observations initially led us to question whether estrogen exerts effects on cell migration and to determine the precise molecular mechanisms involved.
Four steps are required for cell migration: protrusion of cytoplasm at the leading edge of the migration front, formation of adhesions with the underlying cell matrix, disassembly of the adhesions at the rear of the cell, and actinmyosin fiber contractions to pull the bulk of the cytoplasm forward (8) . The first step involves the protrusion of lamellipodia and filopodia at the cell's leading edge. At these points of extension, adhesions to the underlying matrix form and serve a function similar to that of suction cups. The adhesions at the rear of the cell are then disassembled and contractile forces move the bulk of the cell forward. Additional adhesions then reform at the rear. Protrusion, adhesion, and disassembly then reoccur serially, allowing movement in a given direction. This process requires a finely tuned sequence of molecular changes involving more than 125 proteins and suggests that multiple pathways are involved (9) . The more important components coordinating the process of migration include the p60 Src tyrosine kinase (c-Src), focal adhesion kinase (FAK), paxillin, epidermal growth factor receptor (EGF-R), phosphatidylinositol (PI)-3-kinase, c-Jun N-terminal kinase (JNK), and MAPK. We considered it important to fully understand the role of estrogens in this process as a means to identify potentially useful drug targets to prevent metastases.
We have reported previously that extranuclear effects of E 2 , in addition to direct nuclear components, activate several signaling pathways in MCF-7 cells in culture. Based on a review of the literature and our prior studies, we developed a working model that could be used as a framework for dissecting out the molecular mechanisms whereby E 2 stimulates cell migration (7, 9 -20) . As shown in Fig. 1 , this model consists of input, nodal point, and output components. The model proposes that E 2 binds to estrogen receptor (ER)␣ and activates c-Src as the input component. This intracellular kinase in turn results in activation of signaling cascades, involving FAK, MAPK, PI-3-kinase, JNK, and the EGF-R. As a result, a complex forms between FAK and paxillin, which acts as a nodal point to integrate downstream signaling. Pathways involving PI-3-kinase and v-crk sarcoma virus CT10 oncogene homolog (CRKII)-dedicator of cytokinesis (DOCK180)-engulfment and cell motility (ELMO) ultimately interact with Rho family GTPase (Rac) and Rho small GTPase proteins, which are known to regulate cell migration.
In this study, we validated a highly reproducible cell migration assay for breast cancer cells and dissected out several components of the molecular steps required for migration. Our results indicate that multiple signaling pathways interact to regulate cell migration and that paxillin and FAK provide a platform to integrate downstream events. A key component is the effect of E 2 to stimulate phosphorylation of paxillin at the tyrosine 118 position (9) . Knock down of paxillin or blockade of its phosphorylation with the c-Src kinase inhibitor, 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo [3,4-d] pyrimidine (PP2), completely abrogated the effects of E 2 on migration. As evidence of the complexity of this process, we demon-
FIG. 1.
Working model of the effects of E 2 on cell migration. This model is a hypothetical construct based on a comprehensive review of the literature and was used as a means of designing and interpreting our experiments. Components of the cell migration signaling pathways are divided into an input phase, a nodal point, and an output phase. This model provides us with a means of integrating the multiple signaling pathways involved in cell migration. In the diagram, we have highlighted the molecules examined in this study in red. Molecules highlighted in blue are upstream kinases or downstream mediators of cell migration not studied in this paper. In this model, E 2 transactivates the EGF-R, perhaps through a G␣13 mediated GTP-coupled protein, and at the same time causes the phosphorylation and activation of cSrc. FAK and paxillin form a complex that acts as a nodal point to initiate downstream effects on the Rac-1, PAK-1, and Rho proteins responsible for migration. c-Src plays a central role in phosphorylating paxillin, in transactivation of the EGF-R, and in binding to FAK (9) . MAPK (ERK1/2) is one of the kinases that phosphorylates and activates paxillin. Downstream, PI-3 kinase activates Akt and VAV2, a guanosine triphosphatase protein exchange factor that is involved in activation of RAC-1. P-130CAS is activated by FAK, which results in the formation of a complex consisting of CRK II, DOCK180, and ELMO. This complex activates RAC-1, leading to activation of PAK-1. MAPK is involved in the regulation of RHO. RAF (MAPK kinase kinase) and MEK (MAPK kinase) are upstream kinases that activate MAPK.
Endocrinology, November 2010, 151(11):5146 -5156 endo.endojournals.orgstrated a role for the EGF-R, PI-3-kinase, JNK, and MAPK on cell migration. Taken together, these studies emphasize the important effect of E 2 on cell migration in addition to its known actions to enhance cell proliferation and prevent cell death. Targeting of the specific steps involved could provide a means to prevent metastasis. 
Materials and Methods

Reagents
Cell cultures and treatments
Hormone-dependent T47D cells were obtained from M.B.A. Djamgoz (Imperial College, London, UK). These cells were routinely grown in an incubator with 95% humidified air 5% CO 2 at 37 C in RPMI 1640 containing phenol red and supplemented with L-glutamine (2 mM) and 10% fetal bovine serum (FBS). In preparation for cell migration assays, the protocol involved initial plating of 20,000 cells/cm 2 in six-well dishes with growth for 4 -5 d until 90 -100% confluence was reached as judged by visual assessment. The cells were then stepped down into phenol red-free media containing 5% charcoal-stripped serum [dextrancoated charcoal (DCC)] and grown for 2 d to allow adaptation. After this, various concentrations of E 2 or specific signaling pathway inhibitors were added.
Cell migration assay
Cell migration assay was developed by slightly modifying the method described by the group of Simoncini et al. (21) . A vertical line was cut with a razor blade in six-well dishes containing confluent cells stepped down to phenol red-free media as described above. The remainder of the cells to the right of the line were scraped away using a rubber policeman. The vertical boundary thus represented the "starting line," and the endpoint of the experiments represented the number of cells crossing this line over 24 h (see example in Fig. 2A ). After scraping away cells, the plates were washed with Hanks' solution, and 2.0 ml of phenol red-free RPMI 1640 medium containing 5% DCC-FBS and gelatin (1 mg/ml) were added. To prevent the confounding effect of cell proliferation, cytosine ß-D-arabinofuranoside hydrochloride (10 M; Sigma, St. Louis, MO), a selective inhibitor of DNA synthesis that does not inhibit RNA synthesis, was added 1 h before the test substances. Media were changed every 12 h, and fresh media containing cytosine ß-D-arabinofuranoside hydrochloride, gelatin, and the various concentrations of E 2 , vehicle, or inhibitors were added. Cells were digitally imaged, and migration distances from the starting line were visualized using phase contrast microscopy every 24 h. Photographs were made from an average of six fields, and the number of cells crossing the line were counted and expressed as mean Ϯ SEM. Initial validation experiments involved counting cells at 24, 48, and 72 h, but 24 h counts provided the most reproducible and efficient time point for routine experiments.
Western blotting
Cells were lysed in lysis buffer, and lysates were sonicated and cleared by centrifugation at 10,000 ϫ g for 10 min. Protein concentrations were determined using Bio-Rad (Richmond, CA) protein assay dye reagent according to the manufacturer's specification. Equal amounts of protein (50 g) were electrophoresed on 10% polyacrylamide gels and transferred to nitrocellulose membranes. Membranes were probed with the indicated antibodies for 2 h at 25 C in 5% BSA in 1ϫ Tris-buffered saline with Tween 20 [50 mM Tris (pH 7.4), 150 mM NaCl, and 0.5% Tween 20] . Target proteins were detected with horseradish peroxidasecoupled secondary antibodies combined with chemiluminescence and exposure to x-ray film. X-ray film was scanned, and densities of the bands of tested molecules were quantified and normalized by the density of total protein using the TotalLab (Newcastle, UK) program. All data presented have been confirmed in at least two other experiments.
Small interfering RNA (siRNA) knockdown of paxillin
T47D cells were plated at a density of 4 ϫ 10 5 in 60-mm plates and cultured for 3 d to 80% confluence. Cells were then transfected with 5 pM paxillin siRNA (Dharmacon RNAi Technologies, Lafayette, CO) duplex (target sequence, CAACUGGAAACCA-CACAUA, GGACGUGGCACCCUGAACA, CCAAACGGCCU-GUGUUCUU, UGACGAAAGAGAAGCCUAA) using Dharma-FECT transfection reagent (Dharmacon RNAi Technologies) according to manufacturers' recommendations. After incubation with siRNA for 24 h, the cells were incubated in phenol red-free RPMI 1640 medium containing 5% DCC-FBS overnight. Cells were treated and assayed for cell migration and protein expression. Control siRNAs consisted of Dharmacon's nontargeting duplex.
Statistical analyses
All data are expressed as the mean Ϯ SE. Statistical significance was determined by Student's t test. The majority of statistical comparisons determined if the various treatments differed statistically significantly from the effects of E 2 at a 1 nM concentration. In the figures showing these results, the E 2 -alone bars lack asterisk, whereas the comparisons with E 2 alone show asterisks if the differences are statistically significant at P Յ 0.05.
Results
Effect of E 2 on migration
The initial set of experiments validated the cell migration assay. As shown in Fig. 2, A and B, 0.1-100 nM of E 2 stimulated migration of T47D cells in a dose-responsive fashion Fig. 2 ).
Role of c-Src, FAK, and paxillin on migration
Our prior data demonstrated that E 2 can activate c-Src through rapid, extranuclear effects in MCF-7 cells (22). Our working model (Fig. 1) suggests that c-Src activation results in the phosphorylation of FAK and paxillin and can influence cell migration. For these reasons, we initially assessed the effects of E 2 on phosphorylation and activation of c-Src, FAK, and paxillin. Cells were exposed to 1 nM 
cules increased again. The second peaks of FAK and paxillin were higher than the early ones (Fig. 3, A-C) . We next questioned whether blockade of c-Src would abrogate the effects of E 2 on cell migration and on downstream kinases. T47D cells were pretreated with vehicle or the c-Src inhibitor, PP2 (5 M), for 60 min before E 2 was added, and then E 2 -induced migration was measured at 24 h. As shown in Fig. 4A, PP2 completely inhibited E 2 -induced cell migration and blocked E 2 -induced paxillin phosphorylation (Fig. 4A, bottom) , demonstrating that c-Src is upstream of paxillin, whose kinase is activated by E 2 treatment.
To determine whether later activation of c-Src contributed to cell migration, we conducted additional wound assays with delayed addition of PP2, 1 h after 
FIG. 4.
A, Effect of the c-Src inhibitor PP2 on cell migration (top) and paxillin phosphorylation at Tyr118 (bottom). T47D cells were pretreated with PP2 (5 M) for 1 h before the addition of 1 nM E 2 . Incubation time with E 2 is 24 h for cell migration assay and 1 h for Western blot analysis. Tyr118 phosphoryated paxillin was quantified by densitometric scanning and normalized by total paxillin. B, Effect of posttreatment of PP2 on cell migration. T47D cells were exposed to E 2 for 1 h, and then PP2 (5 M) was added. Cell migration was assessed at 24 h of E 2 treatment. C, Effects of siRNA targeted to paxillin on paxillin protein and E 2 -induced paxillin phorphorylation (top) and migration (bottom). ␤-Actin served as a loading control and off target protein. adding E 2 . Similar to the results shown in Fig. 4A , PP2 1 h after E 2 completely abrogated E 2 -induced migration, indicating that sustained activation of this pathway is required for E 2 -stimulated migration of T47D cells (Fig. 4B) .
To directly evaluate the requirement of paxillin for E 2 -mediated migration, we used a siRNA to knock down paxillin and examined the effect of this maneuver on E 2 -induced cell migration. First, we examined the efficiency of knock down. After siRNA transfection, the levels of total paxillin protein and E 2 -induced paxillin phosphorylated protein (but not the nontarget protein ␤-actin) were substantially reduced compared with scrambled (nontarget) siRNA-treated cells (Fig. 4C, top) . We then examined the effect of paxillin knock down on cell migration. T47D cells treated with paxillin siRNA no longer responded to E 2 with increased cell migration (Fig. 4C, bottom) . Taken together, these data strongly support a role for c-Src, FAK, and paxillin in the process of E 2 -induced T47D cell migration and the requirement of sustained activation of c-Src.
Role of ERK1/2 (MAPK)
The ERK subfamily of the MAPK plays a crucial role in the regulation of cell migration (20) . To systematically investigate the role of ERK1/2 on E 2 -induced migration in T47D cells, we initially examined the degree of stimulation of ERK1/2 with E 2 . The cells were treated with 1 nM E 2 for, 5, 15, 30, 60 min and 2, 4, 8, and 24 h. Activation of ERK1/2 was determined by the amount of phospho-ERK1/2 using Western blotting. ERK1/2 activation increased at 5 min, peaked at the 60-min time point, and then fell to the control levels thereafter (Fig. 5A) . The ERK1/2 inhibitor (U0126) blocked this activation (Fig. 5B) . E 2 stimulated MAPK only during the first 60 min but not later in contrast to the early and late effects on c-Src, FAK, and paxillin. Accordingly, we questioned if blockade of MAPK early but not late might inhibit migration. T47D cells were treated with U0126 1 h before 1 nM E 2 and compared with cells where the U0126 was delayed by 60 min. Early but not late inhibition of ERK by U0126 exhibited an inhibitory effect on cell migration (Fig. 5D ). These results suggest that for MAPK, the rapid signaling event is the predominant driving force for E 2 -induced cell migration. Once the rapidly induced signal is transmitted, the cell migration process is not stopped by blocking ERK activation.
Role of EGF-R
Our working model suggests that EGF-R is activated by E 2 and that blockade of this receptor should inhibit migration. Our prior studies had demonstrated in MCF-7 cells that E 2 transactivates EGF-R in a rapid, ER-dependent, extranuclear fashion (23). As shown in Fig. 6 , AG1478, a specific EGF-R tyrosine kinase inhibitor, blocked cell migration.
Role of PI-3-kinase
In a variety of cellular systems, E 2 activates PI-3-kinase in a rapid, extranuclear fashion. We assessed the rapid effect of E 2 in our model by examining the activation of the downstream target of PI-3-kinase, Akt. As shown in Fig.  7A , top and bottom, E 2 caused the phosphorylation and activation of Akt at Ser473, with initial stimulation at 5 min and maximal stimulation at 60 min. The peak levels of phosphorylated Akt were maintained for at least 8 h before reduction, but a peak at 24 h was not observed. This effect was blocked by the PI-3-kinase inhibitor, LY 294002, and by the c-Src inhibitor PP2 (Fig. 7B, top and  bottom) . As evidence of the biologic effects on cell migration, LY 294002 partially inhibited cell migration (Fig. 7C) . The lack of complete blockade of E 2 stimulation suggested that the PI-3 kinase pathway is only a partial mediator of cell migration, as predicted by working model in Fig. 1 .
Role of JNK
JNK is one of panoply of kinases that can phosphorylate paxillin at both serine and tyrosine sites and enhance its ability to mediate cell migration. These various kinases include p21-activated kinase (PAK), c-Src, MAPK, p38 kinase, p90 ribosomal S6 kinase, CDC5, ABL tyrosine kinase, and RACK1, as well as JNK (9) . To examine whether E 2 stimulated JNK phosphorylation, we collected lysates of T47D cells stimulated with E 2 for 5, 15, 30, and 60 min and 2, 4, 8, and 24 h. The amount of phosphorylation of JNK was determined by Western blottings. E 2 increased the level of JNK phosphorylation, which reached a maximum at 1 h and then was reduced. A second increase in phosphorylated JNK occurred at 8 h and remained high at 24 h (Fig. 8A, top and bottom) . To determine the biologic effect of JNK on E 2 -induced cell migration, we used the specific JNK inhibitor, SP600125. We preexposed cells to 10 M SP600125 for 60 min and then added 1 nM E 2 for 24 h. Specific inhibition of JNK by SP600125 significantly reduced E 2 -induced migration (Fig. 8B) . The result suggested that E 2 mediates T47D cell migration via JNK signaling pathways.
Role of moesin
The group of Simoncini and co-workers (24) demonstrated a role for moesin in estrogen and progestin-stimulated breast cell migration by examining moesin phosphorylation and blockade of migration by the Rho-associated protein kinase (ROCK) inhibitor Y27632. In our cellular system, we were unable to demonstrate an effect of E 2 either to enhance phosphorylation of moesin or to block cell migration with Y27632 (10 M) (Supplemental Fig. 3,  top and bottom) .
Discussion
Aromatase inhibitors and antiestrogens block metastatic cancer spread as well as tumor growth in women with hormone-dependent breast cancer (1, (25) (26) (27) ). Demonstration of an effect of E 2 on cell migration in a model system provided evidence of the mechanisms whereby specific targeted agents could potentially modulate the metastatic process. Our studies clearly demonstrated that E 2 stimulates cell migration in a model of hormone-dependent breast cancer and identified several key signaling pathways involved. The effects of E 2 were mediated through ER␣ and resulted in both early and late phosphorylation and activation of c-Src. The function of c-Src persisted beyond the early phase, because delayed addition of a c-Src inhibitor 60 min after addition of E 2 still blocked cell migration. E 2 also produced downstream effects on FAK, ERK, PI-3-kinase, JNK, and paxillin, which appeared to be mediated by an upstream effect of c-Src. As evidence of the biologic relevance of each of these steps, blockade with specifically targeted inhibitors abrogated cell migration. These results are consistent with our working model, as shown in Fig 1, which suggests that each of these steps is interlinked and represents a complex regulatory system controlling cell migration. E 2 induced only early but not late effects on MAPK (ERK1/2) as opposed to both early and late effects on c-Src, FAK, and paxillin phosphorylation. Inhibitor studies demonstrated that late inhibition of MAPK did not affect cell migration, whereas early inhibition did. These observations clearly dissociate the mechanistic effects of MAPK and c-Src. These results suggest that E 2 can stimulate an integrated series of events affecting both rapid, extranuclear, as well as nuclear signaling. result in transcription of a subset of E 2 -regulated genes that are not associated with ER binding to nuclear estrogen response elements. These observations suggest that rapid effects of E 2 can be integrated later with more classical transcriptional events. Based on this reasoning, we cannot readily dissociate extranuclear from nuclear actions of E 2 on cell migration. However, our data highlight the contrast between the late actions of E 2 on c-Src, FAK, and paxillin with the early actions on MAPK. These observations suggest that the effects of E 2 on migration probably involve both rapid extranuclear and later transcriptional events. From a cancer biology perspective, our findings illustrate the ability of neoplastic cells to use multiple signaling pathways to mediate a specific effect. Cancer cells are known to exhibit a high degree of plasticity and have the potential of adapting to various therapeutic strategies with up-regulation of alternative pathways not specifically targeted (29). Because several different inhibitors used in our studies blocked cell migration, the steps involved serve as potential targets for prevention of metastases in women with breast cancer.
These studies, to our knowledge, are the first to demonstrate that E 2 causes phosphorylation and activation of paxillin in breast cancer cells. Paxillin, a scaffold protein present in focal adhesions, has four LIM domains (LIM 1-LIM 4), two of which, LIM 2 and LIM 3, mediate focal adhesion targeting (9) . At the N-terminal portion of the paxillin molecule is a polyproline-rich area that binds Src. Five LD domains also reside in the N-terminal and midportions of paxillin. Particularly important is the LD 4 domain, which regulates focal adhesion turnover and localized lamellipodia formation through Rho guanosine triphosphatase proteins. Paxillin can be phosphorylated at multiple tyrosine, serine, and threonine sites throughout the paxillin molecule by PAK, FAK, Src, JNK, MAPK, p38 kinase, p90 RSK, CDC5, ABL tyrosine kinase, and RACK1 (9) . The tyrosine 118 domain (Y118) of paxillin can be considered an integrator region (30 -33). Through this site, multiple signaling pathways can alter cell migration through downstream events. Both Src and FAK phosphorate Y118 and Y31, key sites for interaction with CRKII-DOCK180-ELMO, which activate the Rac and Rho proteins that ultimately regulate migration (9) .
The role of E 2 on cell migration has been a controversial issue for some time. Rochefort et al. (34) and Rochefort and co-workers (35) initially reported that E 2 blocked cell migration and wound healing in hormone-dependent, MCF-7 breast cancer cells. Other reports also suggested an antimigratory effect of estrogen (36) . However, our prior publication (22) demonstrating that E 2 caused a rapid increase in dynamic membrane structures, including filopodia, lamellipodia, and pseudopodia and localization of ER␣ near the plasma membrane, stimulated others to look for stimulatory effects on migration. The Planas-Silva, Simoncini, Chakravarty, and other laboratories have studied the effects of E 2 on the migration of vascular epithelial cells, endometrial cells, and breast cancer cells (21, (37) (38) (39) (40) . The Simoncini group demonstrated a rapid, extranuclear effect of E 2 on migration in vascular endothelial cells and identified the phosphorylation of moesin as a key event in FAK activation (21) . FAK contains several functional components, including the FERM (erythrocyte band four, 1-ezrin-radixin-moesin) domain, which binds growth factor receptors such as the EGF-R and integrin subunits (10 -12) . The Simoncini group demonstrated that a Rho kinase family member, ROCK, is responsible for moesin phosphorylation, and blockade of ROCK with Y27632 inhibits cell migration (24, 41, 42) . His group demonstrated this effect in T47D breast cancer cells as well as in vascular endothelium. We have not been able to replicate this finding in T47D and MCF-7 cells (24) and currently have not provided a mechanistic reason for the divergence of results between our laboratories. A likely explanation is that we used T47D cells of different lineage or under slightly altered conditions. It may be that with continuous culture, T47D cells from various sources depend to a greater or lesser extent on moesin for cell migration. With so many pathways involved, it is not surprising that some cell lines might use differing pathways to a greater extent than others.
We have not yet examined the downstream mediators of cell migration such as guanine nucleotide exchange factor vav2 (VAV2), CRKII-DOCK180-ELMO, RAC-1, PAK-1, and RhoA. PI-3-kinase, which is activated by E 2 , should result in the phosphorylation of VAV2, which acts as a guanosine triphosphatase protein exchange factor and catalyzes the conversion of GDP-Rac to GTP-Rac (active RAC-1) (14). PAK-1 is then activated by Rac-1, and dynamic membrane changes are initiated by more downstream effectors (16) . Rac-1 stimulates formation of lamellipodia, cdc42 filopodia, and RhoA influences the maturation of adhesions at the leading edge and disassembly of adhesions at the rear. P130CAS is also a key downstream mediator of migration. After phosphorylation by c-Src, this protein binds to CRKII-DOCK180-ELMO and activates Rac-1. The next step, activation of PAK-1 controls stress fiber formation, focal adhesion maintenance, MAPK and JNK signaling cascades, and vascular endothelial growth factor expression (9) .
A critical question regarding cell culture studies is whether similar results can be reproduced in other cell lines. We initially began to develop the cell migration assay in MCF-7 cells and found the degree of stimulation with E 2 to be less robust than in T47D cells (see Supplemental data). Nonetheless, we demonstrated stimulation of MCF-7 cell migration with 1-100 pM E 2 in a dose-dependent fashion, which could be blocked by fulvestrant, PP2, and AG 1478. As noted above, Simoncini and co-workers (24) also demonstrated estrogen stimulation of vascular endothelial as well as MCF-7 cells in their studies, and Kumar and co-workers (39) showed stimulation of endometrial cancer cells. Taken together, it is likely that the stimulation of cell migration by E 2 is a phenomenon inherent in multiple benign and malignant cell types and is not limited to the T47D line.
The studies described considerably extend those of Simoncini et al. (21) and Simoncini and co-workers (24) by demonstrating a mechanistic role for MAPK, PI-3-kinase, JNK, and paxillin in estrogen-induced cell migration. The Simoncini group did demonstrate effects of MAPK and PI-3-kinase inhibitors on moesin phosphorylation induced by progesterone and medroxyprogesteron 17-acetate (38), but they did not examine such effects in estrogenstimulated breast cancer cells. From all of the available data, it would appear that both estrogen and progestins alter migration via multiple mechanisms and that further study will be required to fully understand this complex process.
Our studies and those of others have demonstrated the key role of c-Src in activation of the MAPK and PI-3-kinase pathways and in increasing the aggressiveness of breast cancers (43) . These observations suggest that a cSrc inhibitor might be an effective agent in the treatment of breast cancer. AstraZeneca (Macclesfield, UK) have developed such an inhibitor, which is currently entering clinical trial (44) . Other potential targets would be inhibitors of ERK or of paxillin. Further studies are being pursued to more precisely determine the role of each of the components of cell migration and the relationship of each of these to estrogen activation.
